TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04081896

Intervention type: OTHER
Intervention: Exercise
Description: Exercise prescribed to participants includes spine-specific strengthening exercises targeting core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do \>20 repetitions. If they are able to reach \>10 but \<20 repetitions, exercise load remains the same. If they are unable to reach 10 repetitions, exercise load is decreased 5-10% at their next visit.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level.~Concurrent interventions may or may not include nutrition education, mindfulness, cognitive behavioral therapy.

Intervention type: OTHER
Intervention: Exercise
Description: Exercise prescribed to participants includes spine-specific strengthening exercises targeting core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do \>20 repetitions. If they are able to reach \>10 but \<20 repetitions, exercise load remains the same. If they are unable to reach 10 repetitions, exercise load is decreased 5-10% at their next visit.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level.~Concurrent interventions may or may not include nutrition education, mindfulness, cognitive behavioral therapy.
Study: NCT01329484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Description: Personalized reminiscence therapy using a computerized system

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training using a computerized system

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
Study: NCT03271229

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Bone Marrow Aspirate (BMAC)
Description: Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
Study: NCT02337504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: community-based care
Description: Will receive HIV care in the community and not in the clinic which is the normal standard of care
Study: NCT03649178

Intervention type: OTHER
Group type: OTHER
Intervention: salt
Description: Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: salt
Description: Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
Study: NCT03784326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV (vein)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgical resection
Study: NCT01062646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal music therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community treatment as usual
Study: NCT03784326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV (vein)
Study: NCT02495649

Intervention type: OTHER
Group type: OTHER
Intervention: [18F]-DOPA
Description: To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease

Intervention type: DEVICE
Group type: OTHER
Intervention: PET-CT
Description: To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
Study: NCT00780468

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing diet plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New diet plan
Study: NCT02691247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS03 Low Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS03 High Dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02169258

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Systemic Strategy
Description: Significant CAD needing further revascularization is defined as patients who have luminal stenosis \> 70% of the major epicardial vessels and bypass graft vessel or their major branches (\> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Strategy
Description: Significant CAD needing further revascularization is defined as patients who have luminal stenosis \> 70% of the major epicardial vessels and bypass graft vessel or their major branches (\> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
Study: NCT03359395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Study: NCT00561821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: one tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: one tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: one tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tablet daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet daily
Study: NCT03648372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intravenous infusion.
Study: NCT02850406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: * Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension
Study: NCT04153162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
Study: NCT01103349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
Study: NCT04632342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301 tablet 300mg
Description: * Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301 tablet 300mg
Description: * Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HL301 tablet
Description: 2 tablets at once, three times a day
Study: NCT01793454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen 40%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen 80%
Study: NCT01103349

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo capsules and/or encapsulated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
Study: NCT02601885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-555
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-555
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-555
Description: Intravenous Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous Infusion
Study: NCT00708994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: * Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~* Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: • Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
Study: NCT02717689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker based adjustment of corticosteroid dose
Description: The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
Study: NCT04262180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Base intervention-Fitbit with EHR integration
Description: Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Base intervention-Fitbit with EHR integration
Description: Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Base intervention-Fitbit with EHR integration
Description: Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching Calls
Description: Non-responders to base intervention will be randomized to coaching calls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Gym
Description: Non-responders to base intervention will be randomized to online gym.
Study: NCT01257451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin 50mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50mg bid
Study: NCT03271229

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma (PRP)
Description: Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
Study: NCT03509467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Information
Description: Personalized information about ways that participants can protect themselves and their child from developing melanoma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Information
Description: Personalized information about ways that participants can protect themselves and their child from developing melanoma.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Information
Description: Standard information about ways that participants can protect themselves and their child from developing melanoma.
Study: NCT02651987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg
Study: NCT03509467

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Information
Description: Standard information about ways that participants can protect themselves and their child from developing melanoma.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DNA Extraction Determination of MC1R Genotypes
Description: After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
Study: NCT06076226

Intervention type: OTHER
Intervention: No intervention, observation study
Description: No intervention, observation study

Intervention type: OTHER
Intervention: No intervention, observation study
Description: No intervention, observation study
Study: NCT03768050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced care for frail elderly
Description: Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning\&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network.
Study: NCT02661347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Study: NCT01726803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Physical Therapy with Usual Care
Description: The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
Study: NCT02661347

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Risperidone
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
Study: NCT04245579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial Memory Training Program (UMAM method)
Study: NCT03509467

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DNA Extraction Determination of MC1R Genotypes
Description: After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA Extraction Determination of MC1R Genotypes
Description: After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA Extraction Determination of MC1R Genotypes
Description: After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
Study: NCT03015948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: a single dose of SHR4640 (n=8) for each dose cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: a single dose of SHR4640 (n=8) for each dose cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: a single dose of SHR4640 (n=8) for each dose cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: a single dose of SHR4640 (n=8) for each dose cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: a single dose of placebo (n=2) for each dose cohort .
Study: NCT01395602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: cabergoline 0.5 mg twice weekly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill twice weekly
Study: NCT04422834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
Study: NCT03007693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will receive JNJ-61393215 for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive JNJ- 61393215 matching placebo for 7 days.
Study: NCT04259970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initiation of CFTR Modulator
Description: Inhaled contrast for MRI occurring at each 4 visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initiation of CFTR Modulator
Description: Inhaled contrast for MRI occurring at each 4 visits.
Study: NCT01011881

Intervention type: OTHER
Intervention: pleural level of procalcitonin
Description: no intervention
Study: NCT02754778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conditional workout
Description: 6 month of regular conditional workout 1-3 times a weak
Study: NCT03195634

Intervention type: DRUG
Intervention: Carvedilol
Description: an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate \>55 beats per minute, or up to 12.5 mg/day